# Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

> **NCT00622895** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Systemic Scleroderma
- Severe Systemic Sclerosis

## Interventions

- **DRUG:** fludarabine phosphate
- **DRUG:** Mycophenolic Acid
- **DRUG:** tacrolimus
- **RADIATION:** total-body irradiation
- **PROCEDURE:** bone marrow transplantation
- **PROCEDURE:** reduced intensity allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** quality-of-life assessment
- **OTHER:** laboratory biomarker analysis
- **OTHER:** flow cytometry
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00622895
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-01
- **Primary completion:** 2011-11-01
- **Final completion:** 2017-08-01
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2018-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622895, "Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00622895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*